In an in vivo murine myeloma model, CD8+ T cells in the bone marrow of MM-relapsed mice expressed higher levels of TIGIT and lower levels of another receptor of CD155, DNAM-1, which can deliver a positive signal in T cells through the binding of CD155, compared with those in control or MM-controlled mice. This evidence concerns the gene TIGIT and plasma cell myeloma.